The latest issue of hepatology, an internationally renowned medical academic journal of gastrointestinal and liver diseases, published online the important research results of the Multidisciplinary Comprehensive Treatment Group (MDT) of Wuhan University People's Hospital (Hubei Provincial People's Hospital) on the epidemiology of liver cancer: Through big data summary and analysis, the current situation and reasons for the significant decline of hepatocellular liver cancer in the United States in the past decade have been summarized and analyzed, providing important reference and reference for China's fight against liver cancer.
The paper is titled "Declining Disease Burden of Hepatocellular Carcinoma in the US, 1992-2017: A Population-Based Analysis" In this study, the People's Hospital of Wuhan University was the only signatory unit for the paper. Professor Fu Zhenming, Deputy Director of the Cancer Center, and Professor Chen Mingkai of the Department of Gastroenterology are the corresponding authors of the paper, professor Wang Bin of hepatobiliary surgery and Han Jianglong, a master's student of the First Clinical College, are the first authors of the paper. This study highlights the long-term cultivation and profound strength of the multidisciplinary comprehensive treatment group of liver cancer in Wuhan University People's Hospital in the field of liver cancer.
Fu Zhenming introduced that in recent decades, although the global public health cause has invested a lot of efforts in the fight against liver cancer, the incidence and mortality rate of liver cancer are still on the rise in the world. According to the 2022 Cancer Statistics 2022 report, liver cancer is the 12th most common malignancy in the United States, accounting for 5th among tumor-related causes of death.
Accordingly, the MDT team of liver cancer in the People's Hospital used the GBD database of the World Health Organization's global burden of disease and the SEER database of surveillance epidemiology and final results of the National Cancer Institute to analyze the incidence, mortality and survival rates of hepatocellular carcinoma in the United States from 1992 to 2017. The results showed that the mortality rate of hepatocellular carcinoma in the United States began in 2013 and decreased significantly (annual percentage change: -3.2%, P
In a subsequent analysis, the team analyzed the factors that may contribute to the decline in the burden of liver cancer disease through an "age-time-cohort model": factors including changes in liver cancer risk factors, advances in vaccination and treatment of hepatitis viruses, and advances in liver cancer diagnosis, staging, and treatment techniques are all potential causes. At the same time, this study also pointed out that if the problems of obesity, alcohol consumption and drug abuse in the young generation in the United States remain unresolved for a long time, the burden of liver cancer-related diseases may return.
Fu Zhenming introduced that in recent years, China's cancer burden has been increasing, and the incidence and mortality of cancer are the first in the world. For every 100 new cancer patients in the world, Chinese account for 21. Specifically in liver cancer, there are 910,000 new liver cancers in the world in 2020, of which 410,000 are new liver cancers in China, accounting for more than 45% of the world. In terms of global liver cancer deaths, China is also the world's first: 830,000 liver cancer deaths in 2020, of which 390,000 died of liver cancer in China.
Fu Zhenming introduced that this study also provides an important reference for the mainland to fight liver cancer and reduce the burden of disease, especially to improve the prognosis of liver cancer patients. The liver cancer MDT team formed by the Cancer Center, The Department of Gastroenterology, and the Department of Hepatobiliary Surgery of Wuhan University People's Hospital has achieved fruitful results in clinical diagnosis and treatment, providing standardized and individualized treatment for a large number of liver cancer patients, and many advanced patients have obtained good treatment effects and even cures. His relevant achievements and experience were also published in Anticancer Drugs ( "Anticancer Drugs" and was widely praised by the industry.
Text/Wen Wei Po reporter qian Zhongjun correspondent Yang Cen Photo/Wuhan University People's Hospital
![This is my twin sister, and she's a sleeping beauty who slept at minus 196°C for 11 years[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)